Cetuximab as Second-Line Therapy in Patients with Metastatic Esophageal Adenocarcinoma: A Phase II Southwest Oncology Group Study (S0415)  by Gold, Philip J. et al.
ORIGINAL ARTICLE
Cetuximab as Second-Line Therapy in Patients with
Metastatic Esophageal Adenocarcinoma
A Phase II Southwest Oncology Group Study (S0415)
Philip J. Gold, MD,* Bryan Goldman, MS,† Syma Iqbal, MD,‡ Lawrence P. Leichman, MD,§
Wu Zhang, MD,‡ Heinz-Josef Lenz, MD,‡ and Charles D. Blanke, MD
Introduction: Esophageal adenocarcinomas commonly express the
epidermal growth factor receptor. This trial assessed the 6-month
overall survival probability in metastatic esophageal cancer patients
treated with cetuximab as second-line therapy.
Methods: This was a multicenter, open-label phase II study of
single-agent cetuximab for metastatic esophageal adenocarcinoma
patients who failed one prior chemotherapy regimen. Adequate
organ function and Zubrod performance status of 0 to 2 were
required. Patients received cetuximab 400 mg/m2 intravenously (IV)
on week 1 and 250 mg/m2 IV weekly thereafter. The primary
objective was to determine 6-month overall survival. Secondary end
points included progression-free survival, response rate, and toxic-
ity. Tumor tissue was collected for correlative studies.
Results: Sixty-three patients were registered, with eight ineligible or
never treated. Fifty-five eligible patients (49 men, 6 women; median
age 61.2 years [range, 30.7–88.5]) were enrolled. Twenty patients
survived more than 6 months for a 6-month overall survival rate of
36% (95% confidence interval [CI]: 24–50%). The median overall
survival was 4.0 months (95% CI: 3.2–5.9). Median progression-
free survival was 1.8 months (95% CI: 1.7–1.9). One partial re-
sponse and two unconfirmed partial responses were observed. Two
patients experienced grade 4 fatigue. There was one treatment-
related death due to pneumonitis. Germline polymorphisms of epi-
dermal growth factor receptor, epidermal growth factor, interleukin
(IL)-8, cyclooxygenase (COX)-2, vascular epidermal growth factor
receptor (VEGF), CCND1, neuropilin 1 (NRP1), and K-ras muta-
tional status were not associated with response or survival.
Conclusions: The 6-month overall survival rate of 36% observed on
this study failed to meet the primary survival objective. Thus,
cetuximab alone cannot be recommended in the second-line treat-
ment of metastatic esophageal cancer.
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It is estimated that in 2009, 16,470 patients will be diag-nosed with esophageal cancer, and that 14,530 will die of
the disease.1 Because a significant proportion of these pa-
tients present with or will develop metastatic disease, the
prognosis is poor. Chemotherapy has had only a minimal
impact on the natural history of metastatic esophageal cancer.
First-line chemotherapy results in median survival of up to
11.2 months.2 Little data exist on the benefit of second-line
therapy, with one study demonstrating a median time to
progression of 7 weeks and a median survival of 5 months3
and another with a median survival of 5.6 months in 423
patients.4 A recent second-line randomized study of irinote-
can versus best supportive care in patients with metastatic
gastric and gastroesophageal adenocarcinomas showed an
improvement in overall survival for the irinotecan arm (123
versus 72.5 days).5 To improve the outcome of patients with
metastatic esophageal cancer, it is imperative that more
effective agents be developed.
The epidermal growth factor receptor (EGFR) is a
commonly expressed transmembrane glycoprotein of the ty-
rosine kinase growth factor receptor family. EGFR is ex-
pressed in many normal human tissues, and activation of this
proto-oncogene results in overexpression in many types of
human tumors cells in culture.6 To inhibit proliferation of
EGFR-rich cells, EGFR antagonists, which block the ligand-
binding site, have been developed. Specifically, monoclonal
antibodies to EGFR have been shown to inhibit the prolifer-
ation of cells that produce both transforming growth factor
and epidermal growth factor (EGF).7 Approximately 65% of
esophageal adenocarcinomas have been shown to overex-
press EGFR, and amplification of the EGFR gene has been
found in approximately 11%. Patients with esophageal
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adenocarcinomas overexpressing EGFR seem to have a
poorer prognosis than those whose tumors do not overex-
press EGFR.8
Cetuximab, a chimerized antibody of the IgG1 sub-
class, was originally derived from a mouse myeloma cell
line.9 Cetuximab blocks binding of EGF and transforming
growth factor- to EGFR and inhibits ligand-induced activa-
tion of this tyrosine kinase receptor. Cetuximab also stimu-
lates EGFR internalization, effectively removing the receptor
from the cell surface for interaction with ligand.10 Studies in
advanced colorectal cancer have shown cetuximab to have
clinical antitumor activity, with an 11% response rate in
monotherapy and a 23% response rate in combination with
irinotecan.11 Cetuximab has also been approved for use in
head and neck cancer with radiotherapy for locally advanced
disease or with platinum-based chemotherapy for recurrent or
metastatic disease.
In a phase I multiple-dose clinical trial conducted to
examine the tolerability of anti-EGFR in patients with ad-
vanced cancer, one of three esophageal cancer patients dem-
onstrated stable disease for 7 months.12
Given the poor prognosis of patients with advanced
esophageal cancer, the preclinical rationale for EGFR antag-
onists, and the early clinical data, this phase II study exam-
ined cetuximab in metastatic esophageal cancer patients who
had failed first-line chemotherapy.
PATIENTS AND METHODS
Patients
Eligibility included the following criteria. (1) A histo-
logic diagnosis of adenocarcinoma of the thoracic esophagus
or gastroesophageal junction. (2) Measurable disease by Re-
sponse Evaluation Criteria in Solid Tumors (RECIST). (3)
One prior regimen of chemotherapy for metastatic or recur-
rent disease. Patients may have received one prior regimen of
adjuvant or neoadjuvant chemotherapy if administered at the
time of initial diagnosis with localized disease. (4) No prior
cetuximab or other therapy targeting the EGF pathway. (5)
Patients were required to have a Zubrod performance status
of 0, 1, or 2 and adequate bone marrow, hepatic, and renal
function. Prior radiation and thoracoabdominal surgery were
allowed.
All patients or their guardians provided written in-
formed consent in accordance with institutional and federal
guidelines that included permission for the submission of
tissue for correlative science. This study (ClinicalTrials.
govIdentifier: NCT00096031) was approved by a local Hu-
man Investigation Committees and was conducted in accord
with an assurance filed with and approved by the Cancer
Therapy and Evaluation Program Central Institutional Re-
view Board, National Cancer Institute, Department of Health
and Human Services.
Study Design
This phase II, open-label, multicenter trial was admin-
istered and monitored by Southwest Oncology Group. Pa-
tients received a loading dose of cetuximab at 400 mg/m2
intravenously (IV) over 2 hours on day 1 and on subsequent
weeks cetuximab at 250 mg /m2 IV over 1 hour. Patients were
premedicated with diphenhydramine 50 mg IV or PO 30 to 60
minutes before cetuximab. Treatment continued until disease
progression or unacceptable toxicity.
Baseline assessments included medical history and
physical examination, performance status, complete blood
count with differential and platelet count, serum chemistries,
diagnostic tumor imaging, and tumor markers as clinically
indicated. During the study, complete blood count with dif-
ferential and platelet count was performed weekly, history
and physical examination were performed every other week,
and serum chemistries were performed at the start of every
4-week cycle.
Patients were monitored for toxicity weekly, with ad-
verse events reported to the Southwest Oncology Group
Statistical Center after every 28-day treatment cycle. Toxicity
was graded according to the National Cancer Institute-Com-
mon Terminology Criteria for Adverse Events version 3
criteria. In addition, serious adverse events were reported to
the NCI through the AdEERS reporting system. Tumor re-
sponse using RECIST criteria was assessed every 8 weeks.
Correlative Science
Genotyping
Formalin-fixed paraffin-embedded tumor samples were
submitted and examined for K-ras mutational status and
polymorphisms for EGFR, EGF, IL-8, VEGF, COX-2,
NRP1, and CCND1. Genomic DNA was extracted using the
QIAamp kit (Qiagen, Valencia, CA). Genotype analysis was
performed for most polymorphisms using polymerase chain
reaction-restriction fragment length polymorphism technique.
Forward and reverse primers were used for polymerase
chain reaction (PCR) amplification, and PCR products were
digested by restriction enzymes (New England Biolab, Ip-
swich, MA). Digested fragments were separated on a 4%
NuSieve ethidium bromide-stained agarose gel. In case no
matching restriction enzyme was found, direct sequencing
was used.
K-ras Mutational Analysis
Genomic DNA from microdissected tumor samples
was extracted, and forward and reverse primers for exon 2,
codon 12, and 13 K-ras mutation were used for PCR ampli-
fication. PCR fragments were sequenced on an ABI 3100A
Capillary Genetic Analyzer (Applied Biosystems, Foster
City, CA) and analyzed in antisense direction for the presence
of heterozygous mutations. DNA sequence analyses were
performed by using the ABI Sequencing Scanner v1.0 (Ap-
plied Biosystems).
Statistical Design
This study was monitored by the Data and Safety
Monitoring Committee of the Southwest Oncology Group.
The primary end point of this trial was overall survival. Based
on historical survival rates in this population, it was judged
that this therapy would be of considerable interest if the
overall 6-month survival probability was 50% or greater but
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would be of no further interest if it was 30% or less.
Secondary objectives included (1) assessment of overall
response rate, (2) progression-free survival and time to
treatment failure, (3) evaluation of toxicity in these pa-
tients, and (4) exploratory analyses of germline polymor-
phisms of genes involved in the EGFR, DNA repair, and
angiogenesis pathways.
A two-stage design was used for patient accrual. Thirty
patients were to be accrued to the first stage. If at least nine
of these survived past 6 months, an additional 25 would be
accrued. Of these 55 patients, if a 6-month survival rate of at
least 42% was observed, the null hypothesis would be re-
jected, and this regimen would be considered for further
study. This design has a power of 90% at a significance level
of 0.04. Overall survival curve was plotted using the Kaplan-
Meier method.13
RESULTS
Patients
The first patient cohort was accrued from February to
November 2005, and the study was temporarily closed to
assess survival in these patients. The observed survival rate
was sufficiently high to reopen the study, and the second
cohort of patients was enrolled from April 2006 to January
2007. In total, 63 patients were registered to this study. Eight
of these patients are excluded from the analysis. Six of these
patients were ineligible: two had a gastric primary; three did
not have metastatic disease; and another patient had insuffi-
cient baseline documentation. Two additional eligible pa-
tients did not receive any treatment and are not evaluable for
any end point. The demographic information and patient
characteristics for the 55 eligible and evaluable patients are
listed in Table 1.
Treatment Efficacy
The median number of cetuximab doses was 7 (range,
1–40). A major treatment deviation was recorded for one
patient who received nonprotocol irinotecan and cisplatin
while on study. Of 55 eligible and evaluable patients, 20
survived at least 6 months for a 6-month overall survival rate
of 36% (95% confidence interval [CI]: 24–50%). The
Kaplan-Meier estimate of median overall survival is 4.0
months (95% CI: 3.2–5.9) (Figure 1). Both median progres-
sion-free survival and time to treatment failure are 1.8 months
(95% CI: 1.7–1.9).
The objective responses to cetuximab are summarized
in Table 2. There were two partial responses and one uncon-
firmed partial response for an overall response rate of 5%
(95% CI: 1–15%). For the nine patients with either a partial
response or stable disease, the median overall survival is 8.3
months (range, 4.1–11.3), and the median progression-free
survival is 4.0 months (range, 3.0–11.3).
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FIGURE 1. The Kaplan-Meier
curve for overall survival in patients
with metastatic esophageal cancer
treated with cetuximab as second-
line therapy.
TABLE 1. Baseline Patient Characteristics
Median age (range) 61 (31–89)
Gender
Male 49 (89%)
Female 6 (11%)
Performance status
0 14 (25%)
1 36 (65%)
2 5 (10%)
Disease status
Initial diagnosis 16 (29%)
Recurrence 39 (71%)
Prior surgery 20 (36%)
Prior radiation 34 (62%)
Number of metastatic sites
1 19 (35%)
2 20 (36%)
3 16 (29%)
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Toxicity
The frequency and severity of cetuximab-related toxic-
ities is shown in Table 2. Two patients experienced grade 4
fatigue. Twenty patients experienced grade 3 toxicities, in-
cluding four patients with grade 3 rash. There was one
treatment-related death due to pneumonitis. Dose reductions
or treatment delays were reported for 29 of 55 patients (53%).
Correlative Science
Sufficient tissue was available for analysis in 42 of 55
patients. The germline polymorphisms studied included
EGFR, EGF, IL-8, COX-2, VEGF, CCND1, and NRP1.
Polymorphisms, as performed in this trial, were not
found to be associated with response, overall survival, pro-
gression-free survival, time to treatment failure, or toxicity
for any of the genes tested.
K-ras mutation was present in 1 of 42 patients (2%).
Table 3 summarizes these findings.
DISCUSSION
This phase II trial examined the efficacy and safety of
single-agent cetuximab in patients with previously treated
metastatic esophageal adenocarcinoma. Patients enrolled on
this trial achieved an overall 6-month survival probability of
36%. This represented a failure to meet the primary objective
of the study. However, the median survival of 4 months is
similar to that reported in the other second-line trials of
chemotherapy in metastatic esophageal adenocarcinoma.3–5
The overall response rate of 5% suggests a similar level of
single-agent activity as that seen with cetuximab in patients
with refractory metastatic colon cancer.14 In metastatic colo-
rectal cancer, the addition of cetuximab to cytotoxic chemo-
therapy increases antitumor response rates.15,16 Phase II trials
in untreated, metastatic gastric, or gastroesophageal junction
adenocarcinoma demonstrated that the combination of cetux-
imab with chemotherapy has a high level of activity, with
response rates greater than 40%.17,18
Treatment with single-agent cetuximab in this setting
was shown to be well tolerated with the frequency of adverse
events comparable with that seen in other trials.14 The fre-
quency and severity of cetuximab-induced rash has been
shown to be associated with both response rate and survival.19
In this study, four patients developed grade 3 rash, three of
whom survived for more than 6 months. The patient who died
of pneumonitis is concerning because current trials are com-
bining cetuximab with radiation and chemotherapy for esoph-
ageal cancer patients. This is in contrast to large studies of
cetuximab in both colorectal and head and neck cancers in
which no cases of pneumonitis were reported.20,21 Nonethe-
less, we recommend that close attention be paid to pulmonary
toxicity for patients on these trials.
Evaluation of tissue for a variety of germline polymor-
phisms failed to show a relationship between genotype and
outcome or toxicity for any of the genes tested, although our
ability to detect any differences was limited by the lack of
objective responses and the small sample size.
Almost all the tumors tested were wild-type K-ras, with
K-ras mutation present in only 1 of 42 patients (2%). Al-
though the three responses in this group of patients were
TABLE 2. Treatment-Related Adverse Events
Adverse Event
Grade 2,
n (%)
Grade 3,
n (%)
Dermatologic 20 (36) 4 (7)
Flu-like symptoms 13 (24) 8 (15)a
Gastrointestinal 16 (29) 4 (7)
Hematologic 3 (5) 1 (2)
Immunological 3 (5) 1 (2)
Infection 2 (4) 1 (2)
Pulmonary 2 (4) 2 (4)b
Metabolic 4 (7) 6 (11)
Neurologic 2 (4) 1 (2)
Pain 9 (16) 5 (9)
a Includes two patients with grade 4 fatigue.
b Includes one patient with grade 5 pneumonitis.
TABLE 3. Results of Biomarker Analyses
Marker n (%)
Median OS
(95% CI), mo pa
CCND1 870AG (n  39)
(rs 17852153)
AA 8 (21%) 2.1 (1.2–5.9) 0.18
AG 23 (58%) 5.5 (3.4–7.2)
GG 8 (21%) 3.7 (1.8–15.9)
EGFR 497 GA (n  38)
(rs 11543848)
AA/AG 31 (81%) 3.9 (3.0–7.1) 0.27
GG 7 (19%) 3.5 (1.8–6.4)
IL-8 251 TA (n  39)
(rs 4073)
AA 8 (21%) 5.7 (3.5–6.4) 0.60
AT 17 (44%) 3.9 (2.4–8.3)
TT 14 (35%) 3.2 (1.3–5.8)
COX-2 8473 TC (n  33)
(rs 5275)
CC 7 (21%) 3.2 (1.6–8.3) 0.69
CT 15 (46%) 3.9 (2.6–6.4)
TT 11 (33%) 4.1 (2.1–8.3)
EGF 61 AG (n  37)
(rs 4444903)
AA 10 (27%) 6.1 (3.2–8.0) 0.94
AG 10 (27%) 3.2 (1.6–8.3)
GG 17 (46%) 3.5 (2.6–7.1)
VEGF 936 CT (n  40)
(rs 3025039)
CC 34 (85%) 3.7 (2.6–5.9) 0.26
CT 6 (15%) 7.7 (5.5–11.5)
NRP-1 CT (n  34)
(rs 3750733)
CC 10 (29%) 6.2 (3.9–11.5) 0.27
CT 16 (47%) 3.7 (1.8–5.8)
TT 8 (24%) 7.7 (2.4–15.9)
a p values from Cox regression test for heterogeneity across subgroups.
OS, overall survival; CI, confidence interval; COX, cyclooxygenase; EGF, epider-
mal growth factor; IL, interleukin; VEGF, vascular endothelial growth factor; NRP,
Neuropilin.
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found in patients with wild-type K-ras tumors, we see no
reason to test patients for K-ras mutational status before
therapy on current clinical trials for patients with adenocar-
cinoma of the esophagus. Low frequency of K-ras mutations
have also been observed in squamous cell carcinoma of the
esophagus (0%) and gastric adenocarcinoma (11%).22,23 This
is in contrast to recent data in colorectal cancer, which clearly
demonstrates a correlation between K-ras status and the
efficacy of anti-EGFR targeted therapy.24,25
This trial failed to meet the primary end point. There-
fore, cetuximab monotherapy is not recommended as second-
line therapy in the treatment of metastatic esophageal adeno-
carcinoma.
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